A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma

被引：11

作者：

Paul, Barry ^{[1
]}

Liedtke, Michaela ^{[2
]}

Khouri, Jack ^{[3
]}

Rifkin, Robert ^{[4
]}

Gandhi, Mitul D. ^{[5
]}

Kin, Andrew ^{[6
]}

Levy, Moshe Y. ^{[7
]}

Silbermann, Rebecca ^{[8
]}

Cottini, Francesca ^{[9
]}

Sborov, Douglas W. ^{[10
]}

Sandhu, Irwindeep ^{[11
]}

Villarreal, Lyssa ^{[12
]}

Murphy, Michael ^{[12
]}

Gu, Lin ^{[12
]}

Chen, Ann

Rajakumaraswamy, Nishanthan ^{[12
]}

Usmani, Saad Z. ^{[13
]}

机构：

[1] Levine Canc Inst, Dept Hematol Oncol & Blood Disorders, Charlotte, NC 28204 USA

[2] Stanford Canc Inst, Stanford Comprehens Canc Ctr, Stanford, CA 94305 USA

[3] Taussig Canc Inst, Dept Hematol & Med Oncol, Cleveland Clin, Cleveland Hts, OH 44195 USA

[4] Rocky Mt Canc Ctr, US Oncol Res, Denver, CO 80218 USA

[5] Virginia Canc Specialists, Gainesville, VA 20155 USA

[6] Wayne State Univ, Barbara Ann Karmanos Canc Inst, Dept Oncol, Detroit, MI 48201 USA

[7] Baylor Univ Med Ctr, Dept Hematol & Med Oncol, Dallas, TX 75246 USA

[8] Oregon Hlth & Sci Univ, Div Hematol Med Oncol, Portland, OR 97239 USA

[9] Ohio State Univ Comprehens Canc Ctr, Dept Internal Med, Columbus, OH 43210 USA

[10] Univ Utah, Huntsman Canc Inst, Dept Internal Med, Salt Lake City, UT 84112 USA

[11] Univ Alberta, Cross Canc Inst, Dept Oncol, Edmonton, AB T6G 1Z2, Canada

[12] Gilead Sci Inc, Foster City, CA 94404 USA

[13] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA

来源：

FUTURE ONCOLOGY | 2023年 / 19卷 / 01期

关键词：

bortezomib; carfilzomib; CD47; daratumumab; dexamethasone; immunotherapy; magrolimab; multiple myeloma; pomalidomide; CD47; BLOCKADE; CELLS; DEXAMETHASONE; LENALIDOMIDE; THALIDOMIDE; ANALOGS;

D O I：

10.2217/fon-2022-0975

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Magrolimab is a monoclonal antibody that blocks CD47, a 'do not eat me' signal overexpressed on tumor cells. CD47 is overexpressed in multiple myeloma (MM), which contributes to its pathogenesis. Preclinical studies have shown that CD47 blockade induces macrophage activation, resulting in elimination of myeloma cells, and that there is synergy between magrolimab and certain anticancer therapies. These findings suggest that magrolimab-based combinations may have a therapeutic benefit in MM. This phase II study investigates magrolimab in combination with commonly used myeloma therapies in patients with relapsed/refractory MM and includes a safety run-in phase followed by a dose-expansion phase. Primary end points include the incidence of dose-limiting toxicities and adverse events (safety run-in) and the objective response rate (dose expansion).

引用

页码：7 / 17

页数：11

共 41 条

[11]

ClinicalTrials.gov, 2022, STUD MAGR COMB PART

[12]

DARZALEX (daratumumab), 2022, Prescribing information

[13]

Daver NG, 2022, J CLIN ONCOL, V40

[14] Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy [J].

Gandhi, Ujjawal H. ;

Cornell, Robert F. ;

Lakshman, Arjun ;

Gahvari, Zhubin J. ;

McGehee, Elizabeth ;

Jagosky, Megan H. ;

Gupta, Ridhi ;

Varnado, William ;

Fiala, Mark A. ;

Chhabra, Saurabh ;

Malek, Ehsan ;

Mansour, Joshua ;

Paul, Barry ;

Barnstead, Alyssa ;

Kodali, Saranya ;

Neppalli, Amarendra ;

Liedtke, Michaela ;

Narayana, Swapna ;

Godby, Kelly N. ;

Kang, Yubin ;

Kansagra, Ankit ;

Umyarova, Elvira ;

Scott, Emma C. ;

Hari, Parameswaran ;

Vij, Ravi ;

Usmani, Saad Z. ;

Callander, Natalie S. ;

Kumar, Shaji K. ;

Costa, Luciano J. .

LEUKEMIA, 2019, 33 (09) :2266-2275

[15] Ex vivo drug sensitivity screening in multiple myeloma identifies drug combinations that act synergistically [J].

Giliberto, Mariaserena ;

Thimiri Govinda Raj, Deepak B. ;

Cremaschi, Andrea ;

Skanland, Sigrid S. ;

Gade, Alexandra ;

Tjonnfjord, Geir E. ;

Schjesvold, Fredrik ;

Munthe, Ludvig A. ;

Tasken, Kjetil .

MOLECULAR ONCOLOGY, 2022, 16 (06) :1241-1258

[16] Cancer cells under immune attack acquire CD47-mediated adaptive immune resistance independent of the myeloid CD47-SIRPα axis [J].

Hendriks, Mark A. J. M. ;

Britsch, Isabel ;

Ke, Xiurong ;

van Wijngarden, Anne P. ;

Samplonius, Douwe F. ;

Ploeg, Emily M. ;

Helfrich, Wijnand .

ONCOIMMUNOLOGY, 2021, 10 (01)

[17] Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy [J].

Hideshima, T ;

Chauhan, D ;

Shima, Y ;

Raje, N ;

Davies, FE ;

Tai, YT ;

Treon, SP ;

Lin, B ;

Schlossman, RL ;

Richardson, P ;

Muller, G ;

Stirling, DI ;

Anderson, KC .

BLOOD, 2000, 96 (09) :2943-2950

[18] Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells [J].

Kim, D. ;

Wang, J. ;

Willingham, S. B. ;

Martin, R. ;

Wernig, G. ;

Weissman, I. L. .

LEUKEMIA, 2012, 26 (12) :2538-2545

[19] Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma [J].

Krejcik, Jakub ;

Casneuf, Tineke ;

Nijhof, Inger S. ;

Verbist, Bie ;

Bald, Jaime ;

Plesner, Torben ;

Syed, Khaja ;

Liu, Kevin ;

van de Donk, Niels W. C. J. ;

Weiss, Brendan M. ;

Ahmadi, Tahamtan ;

Lokhorst, Henk M. ;

Mutis, Tuna ;

Sasser, A. Kate .

BLOOD, 2016, 128 (03) :384-394

[20] Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myelorna [J].

Kuhn, Deborah J. ;

Chen, Qing ;

Voorhees, Peter M. ;

Strader, John S. ;

Shenk, Kevin D. ;

Sun, Congcong M. ;

Derno, Susan D. ;

Bennett, Mark K. ;

Van Leeuwen, Fijs W. B. ;

Chanan-Khan, Asher A. ;

Orlowski, Robert Z. .

BLOOD, 2007, 110 (09) :3281-3290

← 1 2 3 4 5 →